THE TAPE

Teladoc Health, Inc.

$8.70▼ −1.14%
Last close
Relative strength
88RS
of 99, against every stock▲ +79 on the month
Powering up
Unconfirmed
+36.8%
six months against the S&P 500
52-week range
−12.0%
from the high
$4.40$9.89
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
No report date on the calendar.
Growth FLATProof PENDING
Quarter to Sep 30, revenue −3% on a year ago
Why it is on no screen

TDOC is off the screens on one check: shallow enough.

A base has formed17.4 weeks, from 5.42 to 9.89.
Long enough to count17.4 weeks against 3 needed.
Shallow enough45.2% deep against 35% allowed.
Close to its pivot-12.0% from the pivot; listed down to -20%.
Relative strengthRS 88 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$8.37
-3.8% · tested 3× · last 4 sessions ago
Resistance above
$9.04
+3.9% · tested 3× · last 12 sessions ago

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Teladoc Health, Inc. is not on any of the screens right now. Its relative strength rating is 88, and it sits in Offices & Clinics Of Doctors Of Medicine.

Against its industry
UnconfirmedNone of the patterns above holds.
One month against the S&P 500
+58.3%
Three months against the S&P 500
+39.5%
Six months against the S&P 500
+36.8%

Its industry has too few members to make an index of, so it is read against the S&P 500 and can only be turning, caution or unconfirmed.

Peers
Same industry
Same theme
No themes — common and fine.
Catalyst roadmap

Nothing dated in the next three months that we can ingest automatically.

How it moves on earnings

On average 14.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business
Revenue
$2.5B
-3.4% year on year
Operating margin
-6.6%
Net margin
-6.3%
Free cash flow
$262.0M
16.5% of market cap
Price to sales
0.64×
Price to earnings
—
not meaningful on a loss

Twelve months to Sep 30, 2026, the four latest quarters in the company’s SEC filings, with the fiscal fourth quarter worked out from the annual report. Revenue growth is the latest quarter against the same quarter a year earlier.

The latest quarter, read by fixed rules · reported Oct 28
Key takeaway
A mixed quarter: the numbers do not agree.
Revenue
$605.1M
-0.3% QoQ · -3.4% YoY
Gross margin
—
Net income
−$26.9M
Loss
Free cash flow
$105.2M
Cash generating

What the numbers say

  • Revenue -3.4% year over year, -0.3% on the quarter
  • Weak: Net loss $27M, narrower than $39M last quarter
  • Good: Cash generating: operating cash flow $106M, free cash flow $105M
  • Good: Net cash $850M · cash $850M
Revenue by quarter
Free cash flow
Net income
shares +2.8% in a year · net cash $849.9M

What is not obvious

  • Weak: Interest $5M a quarter against an operating loss: the debt is carried by the balance sheet, not operations

The desk’s own read

Flagged as drifting up since the report

Final read
Growth: FLAT · Economic proof: PENDING
Key question: What turns the cash flow positive?
The next test is operating profit: net loss $27M, narrower than $39M last quarter.

From the company’s 10-Q and 10-K filings, by Market Desk’s rules. Every line, the takeaway and the final read are fixed rules on the filed numbers; nothing reads the press release, and none of it enters a screen or a rating. Every recent reporter.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Tightening after a sharp runTape · 2026-11-14
range halved after a +54% thrust, at 8.80
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
Tightening after a sharp runTape · 2026-11-10
range halved after a +54% thrust, at 8.98
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
GappedTape · 2026-11-07
-6.8%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-05
above 20d & 50d on 1.6x volume at 9.70
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-05
+9.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-30
+26.9%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Moved 5%+ up on earningsTape · 2026-10-30
+26.9% on earnings 2026-10-28
No measurable effect: stocks behave like random ones over the next three sessions (604 cases over 42 nights).
Unusual volumeTape · 2026-10-30
13.5 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
21
$1,088,130 total

Sold: Catapano Joseph Ronald, DIVITA CHARLES III, Rodrigues Fernando M., Nueno Carlos, Vandervoort Adam C, Bliss Kelly.

Not counted above: 36 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-10-02 Catapano Joseph Ronald · Chief Accounting Officersell655$3,703
2026-10-01 Catapano Joseph Ronald · Chief Accounting Officeroption exercise2,083
2026-09-11 DIVITA CHARLES III · CHIEF EXECUTIVE OFFICER, Directorsell17,805$108,682
2026-09-10 DIVITA CHARLES III · CHIEF EXECUTIVE OFFICER, Directoroption exercise3,642
2026-09-10 DIVITA CHARLES III · CHIEF EXECUTIVE OFFICER, Directoroption exercise39,160
2026-09-03 Rodrigues Fernando M. · President of BetterHelpsell9,812$63,876
2026-09-02 Nueno Carlos · President, Internationalsell6,200$39,066
2026-09-02 Vandervoort Adam C · CHIEF LEGAL OFFICER, SECRETARYsell7,573$47,717

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy1
Buy5
Hold16
Sell1
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

No option open interest for this company. Most listed names have no options at all, and we only read chains for names carrying a dated event, so this is a normal reading rather than a fault.

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Teladoc Health, Inc. (TDOC) — The Tape